MX2020003665A - Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo. - Google Patents

Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.

Info

Publication number
MX2020003665A
MX2020003665A MX2020003665A MX2020003665A MX2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A
Authority
MX
Mexico
Prior art keywords
transdermal
guanfacine
therapeutic system
additive
transdermal therapeutic
Prior art date
Application number
MX2020003665A
Other languages
English (en)
Inventor
Marco Emgenbroich
Eva - Marie Prinz
Elke Klein
Heike Kluth
Xavier Thomas
Linda Sue Nartker
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2020003665A publication Critical patent/MX2020003665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un sistema terapéutico transdérmico para la administración transdérmica de guanfacina que comprende una estructura de capa que contiene guanfacina, dicha estructura de capa comprende: A) una capa de refuerzo; y B) una capa que contiene guanfacina; en donde el sistema terapéutico transdérmico comprende al menos un polímero y al menos un aditivo.
MX2020003665A 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo. MX2020003665A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570745P 2017-10-11 2017-10-11
EP17205546 2017-12-05
PCT/EP2018/077792 WO2019072998A1 (en) 2017-10-11 2018-10-11 TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL DELIVERY OF GUANFACIN HAVING AT LEAST ONE ADDITIVE

Publications (1)

Publication Number Publication Date
MX2020003665A true MX2020003665A (es) 2020-10-01

Family

ID=63878660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003665A MX2020003665A (es) 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.

Country Status (11)

Country Link
US (1) US20200397715A1 (es)
EP (1) EP3694498A1 (es)
JP (1) JP7445218B2 (es)
KR (1) KR20200070306A (es)
CN (1) CN111447926B (es)
AU (1) AU2018348802A1 (es)
BR (1) BR112020007011A2 (es)
CA (1) CA3079697A1 (es)
MX (1) MX2020003665A (es)
TW (1) TWI829654B (es)
WO (1) WO2019072998A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079696A1 (en) 2017-10-11 2019-04-18 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer
EP4395749A1 (en) * 2021-08-30 2024-07-10 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
WO2024040897A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 沙利度胺或其类似物透皮贴剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62289514A (ja) * 1986-04-03 1987-12-16 ハ−コン　ラボラトリ−ズ　コ−ポレ−シヨン 薬理活性物質を経皮、経口又は皮下移植により投与する為の製品
JPH01265021A (ja) * 1987-10-29 1989-10-23 Hercon Lab Corp 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
JPH07145048A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
DE69922257T2 (de) * 1998-07-29 2005-11-10 Teijin Ltd. Druckempfindliche klebstoffzusammensetzung und feuchtigkeitsdurchlässiges, druckempfindliches klebeband, druckempfindliche, pharmazeutische klebstoffzusammensetzung und herstellung eines druckempfindlichen klebebandes welches diese zusammensetzung enthält
CN100411692C (zh) * 2004-01-13 2008-08-20 北京康倍得医药技术开发有限公司 丙烯酸基粘合剂组合物及其药物组合物和透皮治疗系统
KR101432698B1 (ko) 2006-06-06 2014-08-22 다우 코닝 코포레이션 실리콘 아크릴레이트 하이브리드 조성물
BRPI1014886B1 (pt) 2009-04-24 2020-02-11 Henkel IP & Holding GmbH Polímeros acrílicos de silicone híbridos, seus métodos de preparação, adesivos e soluções de uma composição adesiva sensível à pressão compreendendo os mesmos.
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
CA2896055C (en) * 2012-12-28 2021-02-16 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
WO2016130408A1 (en) 2015-02-09 2016-08-18 Dow Corning Corporation Multi-phase silicone acrylic hybrid visco-elastic compositions and methods of making same
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING

Also Published As

Publication number Publication date
EP3694498A1 (en) 2020-08-19
JP2020536882A (ja) 2020-12-17
CN111447926B (zh) 2024-04-30
AU2018348802A1 (en) 2020-04-16
JP7445218B2 (ja) 2024-03-07
US20200397715A1 (en) 2020-12-24
BR112020007011A2 (pt) 2020-10-06
TW201927295A (zh) 2019-07-16
KR20200070306A (ko) 2020-06-17
RU2020115562A3 (es) 2022-02-10
CN111447926A (zh) 2020-07-24
RU2020115562A (ru) 2021-11-15
TWI829654B (zh) 2024-01-21
WO2019072998A1 (en) 2019-04-18
CA3079697A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
BR112016012615A8 (pt) sistemas, e kit
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CR20160289A (es) Compuestos de inhibidor de autotaxina
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
BR112016018455A2 (pt) composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto.
CO6571889A2 (es) Antidotos anticoagulantes
CO2017005500A2 (es) Método para la producción de un sistema de administración farmacéutica
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
BR112018008103A2 (pt) análogos de celastrol
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112017005361A2 (pt) emplastro de opipramol
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.